DeepMed Research

ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis

Completed

Conditions: Psoriasis

First Posted Date: 2010-05-20

Last Posted Date: 2012-10-25

Lead Sponsor: Abbott

Target Recruit Count: 103

Registration Number: NCT01126619

Locations: 🇹🇷
Site Reference ID/Investigator# 44102, Kirikkale, Turkey
🇹🇷
Site Reference ID/Investigator# 44105, Zonguldak, Turkey
🇹🇷
Site Reference ID/Investigator# 38773, Malatya, Turkey

and more 22 locations

Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension

Completed

Conditions: Essential Hypertension

First Posted Date: 2010-05-20

Last Posted Date: 2012-05-01

Lead Sponsor: Abbott

Target Recruit Count: 3828

Registration Number: NCT01127139

Locations: 🇨🇿
Site Reference ID/Investigator# 40910, Beroun, Czech Republic
🇨🇿
Site Reference ID/Investigator# 42083, Brumov, Czech Republic
🇨🇿
Site Reference ID/Investigator# 38836, Bystrice nad Pernstejnem, Czech Republic

and more 131 locations

Exploratory Biomarker Study of Cerebrospinal Fluid in Healthy Volunteers

Completed

Conditions: Healthy

Interventions: Other: Sampling Rate

First Posted Date: 2010-05-19

Last Posted Date: 2010-05-19

Lead Sponsor: Abbott

Target Recruit Count: 8

Registration Number: NCT01126567

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

Phase 1

Completed

Conditions: Sleep Disorder

Interventions: Drug: ABT-652
Drug: Placebo

First Posted Date: 2010-05-17

Last Posted Date: 2011-07-04

Lead Sponsor: Abbott

Target Recruit Count: 36

Registration Number: NCT01124851

Locations: 🇺🇸
Site Reference ID/Investigator# 43241, Phoenix, Arizona, United States
🇺🇸
Site Reference ID/Investigator# 38092, Glendale, California, United States
🇺🇸
Site Reference ID/Investigator# 43264, San Diego, California, United States

and more 2 locations

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ABT-869
Drug: ketoconazole

First Posted Date: 2010-05-03

Last Posted Date: 2011-07-26

Lead Sponsor: Abbott

Target Recruit Count: 12

Registration Number: NCT01114191

Locations: 🇺🇸
Site Reference ID/Investigator# 35784, Detroit, Michigan, United States
🇺🇸
Site Reference ID/Investigator# 36527, Lebanon, New Hampshire, United States

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Ankylosing Spondylitis

Interventions: Biological: adalimumab
Other: placebo

First Posted Date: 2010-05-03

Last Posted Date: 2011-12-01

Lead Sponsor: Abbott

Target Recruit Count: 344

Registration Number: NCT01114880

Locations: 🇨🇳
Site Reference ID/Investigator# 24056, Guangzhou, China
🇨🇳
Site Reference ID/Investigator# 24054, Hefei, Anhui, China
🇨🇳
Site Reference ID/Investigator# 25522, Beijing, China

and more 6 locations

Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection

Completed

Conditions: Tracheitis
Tracheobronchitis
Bronchitis
Chronic Bronchitis
Community-acquired Pneumonia

First Posted Date: 2010-04-21

Last Posted Date: 2011-09-13

Lead Sponsor: Abbott

Target Recruit Count: 3181

Registration Number: NCT01108185

Locations: 🇸🇰
Site Reference ID/Investigator# 37753, Banska Bystrica, Slovakia
🇸🇰
Site Reference ID/Investigator# 37758, Banska Bystrica, Slovakia
🇸🇰
Site Reference ID/Investigator# 37827, Bratislava, Slovakia

and more 155 locations

Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection

Completed

Conditions: Respiratory Syncytial Virus Infection

Interventions: Biological: Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.

First Posted Date: 2010-04-21

Last Posted Date: 2012-10-31

Lead Sponsor: Abbott

Target Recruit Count: 82

Registration Number: NCT01107535

Locations: 🇵🇪
Site Reference ID/Investigator# 27834, Arequipa, Peru
🇵🇪
Site Reference ID/Investigator# 27836, Lima, Peru
🇵🇪
Site Reference ID/Investigator# 6059, Callao, Peru

and more 1 locations

Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs)

Completed

Conditions: HIV Infection

First Posted Date: 2010-04-14

Last Posted Date: 2011-12-14

Lead Sponsor: Abbott

Target Recruit Count: 94

Registration Number: NCT01103596

Locations: 🇫🇷
Site Reference ID/Investigator# 27801, Angers, France
🇫🇷
Site Reference ID/Investigator# 27799, Bordeaux, France
🇫🇷
Site Reference ID/Investigator# 27800, Nantes, France

and more 16 locations

Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis and Mild Community-acquired Pneumonia in Common Clinical Practice in Ukraine

Completed

Conditions: Respiratory Tract Infections

Interventions: Drug: Clarithromycin (Klacid SR)

First Posted Date: 2010-03-30

Last Posted Date: 2011-07-11

Lead Sponsor: Abbott

Target Recruit Count: 2822

Registration Number: NCT01095978

Locations: 🇺🇦
Site Reference ID/Investigator# 29839, Kiev, Ukraine
🇺🇦
Site Reference ID/Investigator# 30540, Kiev, Ukraine
🇺🇦
Site Reference ID/Investigator# 40759, Kyiv, Ukraine

and more 123 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy